Between 14 February and 20 February, 10,800 jobs were posted by 311 companies, according to the GlobalData jobs analytics tool. This was a 16% decrease on the week before, when 346 medtech companies filed 12,814 listings.

Yet again, eye health business Bausch + Lomb posted the most roles, with 859 filed across the course of the week. It was once again followed by Biotronik, which posted 527 jobs, but Sonova Holding was pipped to the third spot by Thermo Fisher, which posted 504 jobs.

Of the 10,800 jobs posted, entry and junior level positions made up 2,896 and 4,509 respectively. Mid-level postings accounted for 3,044 of the jobs while there were 351 senior listings.

Busy times for Bausch

Despite the impact of the Covid-19 pandemic, Bausch + Lomb parent company Bausch Health appeared to be turned towards recovery when announcing its Q4 2020 results this week. Despite a net loss of $153m, the firm generated revenues of $2.2bn during this time.

Bausch Health chairman and CEO Joseph Papa said: “Despite unprecedented business challenges resulting from the Covid-19 pandemic, I’m proud that Bausch Health finished the year strong and outperformed the high end of our latest revenue guidance range.

“During the pandemic-related downturn, we focused our efforts on growing market share for key promoted products, carefully managed our expenses and continued to invest in our pipeline for future growth opportunities. We generated cash from operations of more than $1.1bn, which helped us to repay approximately $900m of our debt.”

Baush + Lomb this week launched the first US Food and Drug Administration (FDA)-approved over-the-counter (OTC) preservative-free antihistamine eye itch relief drop. The formula is designed to block the release of histamines that cause puffy, itchy eyes during hayfever season.

The firm made up approximately 56% of parent company Bausch Health’s Q4 2020 revenue, and 55% of its overall 2020 revenue.